Comparative in vitro antipseudomonal activity of ceftolozane/tazobactam against Pseudomonas aeruginosa isolates from children with cystic fibrosis.
This study evaluated the in vitro activity of Ceftolozane/tazobactam (C/T) vs 10 comparator agents against Pseudomonas aeruginosa isolates obtained from clinical respiratory samples from pediatric patients with cystic fibrosis at three hospitals during 2015 to 2020. Antimicrobial susceptibility testing was performed using microbroth dilution technique with custom prepared Sensititre® MIC plates. MICs were determined via Sensititre Vizion® system and results were interpreted using current CLSI and EUCAST (2022) breakpoint criteria. C/T was the most potent agent as compared with other antipseudomonal drugs against 291 isolates with MIC50 = 1 μg/mL and MIC90 = 2 μg/mL with percent susceptibility as 95.2%. C/T remained active against majority of ß-lactam non-susceptible isolates; percent susceptibility ranging from 61.2% to 80% including 65.9% ceftazidime non-susceptible isolates. C/T had high activity against P. aeruginosa from 3 geographically diverse pediatric medical centers. Study results suggest that C/T may be used as a potential therapeutic option for treating pediatric patients with CF.
Diagnostic microbiology and infectious disease
Humans; Child; Pseudomonas aeruginosa; Anti-Bacterial Agents; Cystic Fibrosis; Enterobacteriaceae; Penicillanic Acid; Enterobacteriaceae Infections; Pseudomonas Infections; Tazobactam; Cephalosporins; Microbial Sensitivity Tests; Drug Resistance, Multiple, Bacterial
Antimicrobial susceptibility; MIC; ceftolozane/tazobactam; cystic fibrosis; pediatric, Pseudomonas
Kanwar N, Harrison CJ, Pence MA, Qin X, Selvarangan R. Comparative in vitro antipseudomonal activity of ceftolozane/tazobactam against Pseudomonas aeruginosa isolates from children with cystic fibrosis. Diagn Microbiol Infect Dis. 2023;105(4):115904. doi:10.1016/j.diagmicrobio.2023.115904